市場調査レポート
商品コード
1059033

脳腫瘍治療薬の世界市場:2021年~2025年

Global Brain Tumor Therapeutics Market 2021-2025

出版日: | 発行: TechNavio | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
脳腫瘍治療薬の世界市場:2021年~2025年
出版日: 2022年01月13日
発行: TechNavio
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の脳腫瘍治療薬の市場規模は、2021年から2025年の間に12億3,000万米ドル成長し、予測期間中は9.67%のCAGRで成長する見込みです。

同市場は、脳腫瘍の有病率の増加と、戦略的提携に牽引されています。

当レポートでは、脳腫瘍治療薬の世界市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、および約25のベンダーをカバーする分析を提供しています。

目次

エグゼクティブサマリー

市場情勢

  • 市場のエコシステム
  • バリューチェーン分析

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 2020年の市場規模
  • 市場の見通し:2020年から2025年の予測

ファイブフォース分析

  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • ライバルの脅威
  • 市況

市場セグメンテーション:タイプ別

  • 市場セグメント
  • タイプ別の比較
  • 低分子:市場規模と予測(2020年~2025年)
  • 生物学的:市場規模と予測(2020年~2025年)
  • タイプ別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別の比較
  • 北米:市場規模と予測(2020年~2025年)
  • 欧州:市場規模と予測(2020年~2025年)
  • アジア:市場規模と予測(2020年~2025年)
  • その他の地域:市場規模と予測(2020年~2025年)
  • 主要国
  • 地域情勢別の市場機会
  • 市場促進要因
  • 市場の課題
  • 市場動向

ベンダー情勢

  • ベンダー情勢
  • 混乱の状況

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Amgen Inc.
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • NextSource Pharmaceuticals LLC
  • Novartis AG
  • Y-mAbs Therapeutics Inc.

付録

目次
Product Code: IRTNTR71849

Technavio has been monitoring the brain tumor therapeutics market and it is poised to grow by $ 1.23 billion during 2021-2025, progressing at a CAGR of 9.67% during the forecast period. Our report on the brain tumor therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of brain cancer and strategic alliances. In addition, the increasing prevalence of brain cancer is anticipated to boost the growth of the market as well.

The brain tumor therapeutics market analysis includes the type segment and geographic landscape.

Technavio's brain tumor therapeutics market is segmented as below:

By Type

  • Small molecules
  • Biologics

By Geographic

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the high morbidity of brain tumorsas one of the prime reasons driving the brain tumor therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on brain tumor therapeutics market covers the following areas:

  • Brain tumor therapeutics market sizing
  • Brain tumor therapeutics market forecast
  • Brain tumor therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading brain tumor therapeutics market vendors that include Amgen Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., NextSource Pharmaceuticals LLC, Novartis AG, and Y-mAbs Therapeutics Inc. Also, the brain tumor therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Type
    • Market segments
    • Comparison by Type
    • Small molecules - Market size and forecast 2020-2025
    • Biologics - Market size and forecast 2020-2025
    • Market opportunity by Type
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • Bristol-Myers Squibb Co.
    • Eisai Co. Ltd.
    • Emcure Pharmaceuticals Ltd.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck and Co. Inc.
    • NextSource Pharmaceuticals LLC
    • Novartis AG
    • Y-mAbs Therapeutics Inc.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations
  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Type - Market share 2020-2025 (%)
  • 22: Comparison by Type
  • 23: Small molecules - Market size and forecast 2020-2025 ($ million)
  • 24: Small molecules - Year-over-year growth 2020-2025 (%)
  • 25: Biologics - Market size and forecast 2020-2025 ($ million)
  • 26: Biologics - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share By Geographical Landscape 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity By Geographical Landscape ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Amgen Inc. - Overview
  • 48: Amgen Inc. - Business segments
  • 49: Amgen Inc. - Key offerings
  • 50: Amgen Inc. - Key customers
  • 51: Amgen Inc. - Segment focus
  • 52: Bristol-Myers Squibb Co. - Overview
  • 53: Bristol-Myers Squibb Co. - Product and service
  • 54: Bristol-Myers Squibb Co. - Key offerings
  • 55: Bristol-Myers Squibb Co. - Key customers
  • 56: Bristol-Myers Squibb Co. - Segment focus
  • 57: Eisai Co. Ltd. - Overview
  • 58: Eisai Co. Ltd. - Business segments
  • 59: Eisai Co. Ltd. - Key offerings
  • 60: Eisai Co. Ltd. - Key customers
  • 61: Eisai Co. Ltd. - Segment focus
  • 62: Emcure Pharmaceuticals Ltd. - Overview
  • 63: Emcure Pharmaceuticals Ltd. - Product and service
  • 64: Emcure Pharmaceuticals Ltd. - Key offerings
  • 65: Emcure Pharmaceuticals Ltd. - Key customers
  • 66: Emcure Pharmaceuticals Ltd. - Segment focus
  • 67: F. Hoffmann-La Roche Ltd. - Overview
  • 68: F. Hoffmann-La Roche Ltd. - Business segments
  • 69: F. Hoffmann-La Roche Ltd. - Key offerings
  • 70: F. Hoffmann-La Roche Ltd. - Key customers
  • 71: F. Hoffmann-La Roche Ltd. - Segment focus
  • 72: GlaxoSmithKline Plc - Overview
  • 73: GlaxoSmithKline Plc - Business segments
  • 74: GlaxoSmithKline Plc - Key offerings
  • 75: GlaxoSmithKline Plc - Key customers
  • 76: GlaxoSmithKline Plc - Segment focus
  • 77: Merck and Co. Inc. - Overview
  • 78: Merck and Co. Inc. - Business segments
  • 79: Merck and Co. Inc. - Key offerings
  • 80: Merck and Co. Inc. - Key customers
  • 81: Merck and Co. Inc. - Segment focus
  • 82: NextSource Pharmaceuticals LLC - Overview
  • 83: NextSource Pharmaceuticals LLC - Product and service
  • 84: NextSource Pharmaceuticals LLC - Key offerings
  • 85: NextSource Pharmaceuticals LLC - Key customers
  • 86: NextSource Pharmaceuticals LLC - Segment focus
  • 87: Novartis AG - Overview
  • 88: Novartis AG - Business segments
  • 89: Novartis AG - Key offerings
  • 90: Novartis AG - Key customers
  • 91: Novartis AG - Segment focus
  • 92: Y-mAbs Therapeutics Inc. - Overview
  • 93: Y-mAbs Therapeutics Inc. - Business segments
  • 94: Y-mAbs Therapeutics Inc. - Key offerings
  • 95: Y-mAbs Therapeutics Inc. - Key customers
  • 96: Y-mAbs Therapeutics Inc. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations